The Anti-Inflammatory Activity of HMGB1 A Box Is Enhanced When Fused with C-Terminal Acidic Tail

HMGB1, composed of the A box, B box, and C tail domains, is a critical proinflammatory cytokine involved in diverse inflammatory diseases. The B box mediates proinflammatory activity, while the A box alone acts as a specific antagonist of HMGB1. The C tail contributes to the spatial structure of A box and regulates HMGB1 DNA binding specificity. It is unknown whether the C tail can enhance the anti-inflammatory effect of A box. In this study, we generated fusion proteins consisting of the A box and C tail, in which the B box was deleted and the A box and C tail were linked either directly or by the flexible linker sequence (Gly4Ser)3. In vitro and in vivo experiments showed that the two fusion proteins had a higher anti-inflammatory activity compared to the A box alone. This suggests that the fused C tail enhances the anti-inflammatory effect of the A box.

• Publication year

  2010

• Venue

  Journal of Biomedicine and Biotechnology

• Publication date

  2010-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1155/2010/915234PMID 20379370PMCID 2850157
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protective Effect of Antagonist of High‐mobility Group Box 1 on Lipopolysaccharide‐Induced Acute Lung Injury in Mice

  2009cited by this paper
• HMGB1 IS MARKEDLY ELEVATED WITHIN 6 HOURS OF MECHANICAL TRAUMA IN HUMANS

  2009cited by this paper
• ROLE OF TOLL-LIKE RECEPTORS 2 AND 4, AND THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN HIGH-MOBILITY GROUP BOX 1-INDUCED INFLAMMATION IN VIVO

  2009influential reference
• Single-chain antibody against human lipocalin-type prostaglandin D synthase: Construction, expression, purification, and activity assay

  2008cited by this paper
• Therapeutic potential of HMGB1-targeting agents in sepsis

  2008cited by this paper
• Bench-to-bedside review: High-mobility group box 1 and critical illness

  2007cited by this paper
• The HMGB1 acidic tail regulates HMGB1 DNA binding specificity by a unique mechanism.

  2007influential reference
• Effects of Acidic Tail on Human HMGB1 Antibacterial Activity

  2006cited by this paper
• The cytokine activity of HMGB1

  2005cited by this paper
• Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function

  2004cited by this paper
• The long acidic tail of high mobility group box 1 (HMGB1) protein forms an extended and flexible structure that interacts with specific residues within and between the HMG boxes.

  2004cited by this paper
• Structural Basis for the Proinflammatory Cytokine Activity of High Mobility Group Box 1

  2003cited by this paper
• Reversing established sepsis with antagonists of endogenous high-mobility group box 1

  2003influential reference
• HMGB1 as a DNA‐binding cytokine

  2002cited by this paper
• Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

  2002cited by this paper
• HMG-1 as a mediator of acute lung inflammation.

  2000cited by this paper
• High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes

  2000cited by this paper
• HMG-1 as a late mediator of endotoxin lethality in mice.

  1999influential reference
• Structure of the HMG box motif in the B‐domain of HMG1.

  1993cited by this paper
• Nonhistone proteins HMG1 and HMG2 change the DNA helical structure.

  1978cited by this paper

• Evaluation of serum HMGB1 levels in assessing the severity of pediatric sepsis and analysis of the therapeutic efficacy of blood purification modalities

  2026cites this paper
• HMGB1: Different secretion pathways with pivotal role in epilepsy and major depressive disorder.

  2025cites this paper
• Dualistic Roles of High Mobility Group Box 1 in Cancer and Inflammation

  2025cites this paper
• Mechanism of action of HMGB1 in urologic malignancies

  2025cites this paper
• HBHP ameliorates CCL4-induced liver fibrosis in rats by inhibiting HMGB1-mediated inflammatory response through binding to the HMGB1-A box.

  2025cites this paper
• Targeting high-mobility-group-box-1-mediated inflammation: a promising therapeutic approach for myocardial infarction

  2024cites this paper
• Probing the interactions of genistein with HMGB1 through multi-spectroscopic and in-silico approaches.

  2024cites this paper
• HMGB1: A New Target for Ischemic Stroke and Hemorrhagic Transformation

  2024cites this paper
• Mechanisms involved in the HMGB1 modulation of tumor multidrug resistance (Review)

  2023cites this paper
• HMGB1 in the interplay between autophagy and apoptosis in cancer.

  2023cites this paper
• High Mobility Group Box 1 Protein: A Plausible Therapeutic Molecular Target in Parkinson's disease.

  2023cites this paper
• HMGB1: a double-edged sword and therapeutic target in the female reproductive system

  2023cites this paper
• HMGB1 cleavage by complement C1s and its potent anti-inflammatory product

  2023influential citation
• The mechanism of HMGB1 secretion and release

  2022cites this paper
• High mobility group box 1 inhibition by BoxA attenuates ovalbumin-induced allergic rhinitis in mice

  2022cites this paper
• MiR-146a alleviates lung injury caused by RSV infection in young rats by targeting TRAF-6 and regulating JNK/ERKMAPK signaling pathways

  2022cites this paper
• Role of high-mobility group box 1 in cancer.

  2022cites this paper
• Chromatin-Associated Molecular Patterns (CAMPs) in sepsis

  2022cites this paper
• Emerging roles of HMGB1-related lncRNA: from molecular biology to clinical application.

  2022cites this paper
• The role of HMGB1 in COVID‐19‐induced cytokine storm and its potential therapeutic targets: A review

  2022cites this paper
• Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2

  2021cites this paper
• Exploring the therapeutic promise of targeting HMGB1 in rheumatoid arthritis.

  2020cites this paper
• HMGB1-induced ILC2s activate dendritic cells by producing IL-9 in asthmatic mouse model.

  2020cites this paper
• High Mobility Group Box 1: An Immune-regulatory Protein

  2019cites this paper
• HMGB1 Antagonist, Box A, Reduces TLR4, RAGE, and Inflammatory Cytokines in the Cornea of P. aeruginosa-Infected Mice

  2018cites this paper
• Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes

  2017cites this paper
• Role of spinal and peripheral HMGB1 in arthritis-induced pain

  2017cites this paper
• Innate immune memory: Implications for host responses to damage‐associated molecular patterns

  2016cites this paper
• Expression and Significance of High-Mobility Group Protein B1 (HMGB1) and the Receptor for Advanced Glycation End-Product (RAGE) in Knee Osteoarthritis

  2016cites this paper
• The Role of HMGB1 in Cardiovascular Biology: Danger Signals

  2015cites this paper
• Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro.

  2015cites this paper
• HMGB1 in health and disease.

  2014cites this paper
• An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.

  2014cites this paper
• Combination of TAT-HMGB1A and R3V6 amphiphilic peptide for plasmid DNA delivery with anti-inflammatory effect

  2014cites this paper
• Hairpin ODN-based ligands as potential inhibitors of HMGB1 cytokine activity

  2013cites this paper
• High-mobility-group box protein 1A box reduces development of sodium laurate-induced thromboangiitis obliterans in rats.

  2013cites this paper
• The C‐terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis

  2010cites this paper